10.20
-0.66 (-6.08%)
| Previous Close | 10.86 |
| Open | 10.85 |
| Volume | 2,366,201 |
| Avg. Volume (3M) | 2,304,195 |
| Market Cap | 1,859,667,072 |
| Price / Earnings (Forward) | 36.90 |
| Price / Sales | 4.67 |
| Price / Book | 107.68 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Profit Margin | -20.25% |
| Operating Margin (TTM) | -5.14% |
| Diluted EPS (TTM) | -0.290 |
| Quarterly Revenue Growth (YOY) | 47.90% |
| Current Ratio (MRQ) | 1.72 |
| Operating Cash Flow (TTM) | -26.71 M |
| Levered Free Cash Flow (TTM) | -5.90 M |
| Return on Assets (TTM) | -3.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Xeris Biopharma Holdings, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 1.50 |
Select this tab to load the latest available analysis.
|
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 4.19% |
| % Held by Institutions | 54.46% |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |